HOME >> MEDICINE >> NEWS
Some Alzheimer's patients can benefit from drug memantine

The drug memantine can reduce cognitive deterioration and loss of everyday functions in patients with moderate to severe Alzheimer's disease, according to a new review of studies.

Memantine's effects are small but "clinically noticeable" after patients take 20 milligrams of the drug daily for 28 weeks, according to Dr. Rupert McShane of the University of Oxford and colleagues. The effect of memantine was measured by a variety of tests that rate a patient's thinking skills, daily activity and mood.

While there is no evidence that the drug can treat agitation in Alzheimer's patients, it does appear to prevent the onset of agitation, the review finds.

The studies also hint at some cognitive benefits from the drug for patients with mild to moderate Alzheimer's and vascular dementia, which occurs when brain cells are starved of oxygen by blocked or diseased blood vessels. However, these changes were not clinically significant, and it remains unknown whether there is a true benefit in mild to moderate cases, McShane and colleagues write.

The Food and Drug Administration approved memantine for the treatment of moderate to severe Alzheimer's dementia in 2003. The European Agency for the Evaluation of Medical Products approved the drug for similar indications in 2002. Manufacturers of the drug in Europe and the United States have applied for approval of the drug for mild to moderate Alzheimer's dementia.

The review appears in the April issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The review included nine published studies comprising 2,339 participants, but three important trials have not yet been published.

To account for the missing data, the Cochrane researchers als
'"/>

Contact: Rupert McShane
rupert.mcshane@psych.ox.ac.uk
Center for the Advancement of Health
19-Apr-2005


Page: 1 2

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Alzheimers disease to quadruple worldwide by 2050
3. Study outlines how stroke, head injury can increase risk of Alzheimers disease
4. Explaining a link between strokes and Alzheimers
5. MU researchers find mechanisms that may unlock answers to Alzheimers disease
6. Blocking stress protein decreases Alzheimers peptide in mice
7. Nursing home placement associated with accelerated cognitive decline in Alzheimers disease
8. Brain inflammation may be friend, not foe, for Alzheimers patients
9. Blood inflammation plays role in Alzheimers disease
10. Alzheimers weight gain initiative also improved patients intellectual abilities
11. Can an omega-3 fatty acid slow the progression of Alzheimers disease?

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/17/2017)... ... February 17, 2017 , ... Corrective Action & ... **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 p.m. ET, ... (CA) and preventive action (PA)? , The methods share techniques and tools but ...
(Date:2/17/2017)... ... , ... Program will serve more than 5,000 kids in ... Foundation announced today that they have awarded nine grants to expand the Foundation’s ... mentoring program, teaches kids the fundamentals of soccer while striving to help them ...
(Date:2/17/2017)... ... February 17, 2017 , ... PrideStaff, a national ... was named to Staffing Industry Analysts' 2017 "Staffing 100 North America" list. ... made notable contributions to the staffing industry over the last twelve months. Industry ...
(Date:2/17/2017)... ... February 17, 2017 , ... Top neuroendocrine cancer doctors, nurses and specialists ... from February 21 - 23 in Beaver Creek, CO. It was announced today by ... second year in Beaver Creek, hosting over 60 faculty members and addressing unmet needs ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati knows ... of research, development and clinical trials, the founder of Chigurupati Technologies has invented ... of FDA approved ingredients that when infused into alcohol, protect the consumer’s liver ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... CINCINNATI , Feb. 17, 2017  Ethicon, ... Torax Medical, Inc., a privately held medical device ... Reflux Management System, a novel minimally invasive ... acquisition of Torax Medical will enable Ethicon to ... the anatomy-altering laparoscopic Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
(Date:2/17/2017)... AMSTERDAM , Feb. 17, ... connected health offerings at the  ...  (NYSE: PHG,AEX: PHIA), a global ... a broad range of population ... personal health solutions, fully integrated in a ...
Breaking Medicine Technology:
Cached News: